Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
P/B ratio for Alpine Immune Sciences, Inc. (ALPN)
P/B ratio as of 2023: 2.91
According to Alpine Immune Sciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.91. At the end of 2022 the company had a P/B ratio of 1.37.
P/B ratio history for Alpine Immune Sciences, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.91 |
| 2022 | 1.37 |
| 2021 | 2.92 |
| 2020 | 4.22 |
| 2019 | 2.39 |
| 2018 | 1.14 |
| 2017 | 0.92 |
| 2016 | 0.63 |
| 2015 | 0.87 |
| 2014 | -8.64 |
| 2013 | -1.49 |
| 2012 | 0.00 |